Abstract: The invention relates to a cosmetic product comprising a two-chamber container for application of cosmetic preparations, characterized in that the first chamber contains a preparation comprising silicic acid (phase 1) and the second chamber a preparation comprising an alkaline compound (base) (phase 2).

Abstract: A hair treatment composition, comprising, by weight of the total composition:—a) from 60 to 80 wt % isododecane, b) from 0.5 to 10 wt % isononyl isononanoate, and c) from 5 to 30 wt % of hydrogenated polyisobutene.

Abstract: Formulations, kits, and methods for rebuilding the disulfide bonds in keratin found in hair, skin, or nails. Hair that is damaged due to a hair coloring treatment and/or other reducing treatment, such as during a permanent wave, can be treated with the formulations containing one or more active agents. The formulations may be applied subsequent to a hair coloring treatment or simultaneously with a hair coloring treatment. Use of the active agent formulations during a permanent wave treatment prevents the reversion of the hair to its previous state, for at least one week, preferably at least three months, more preferably at least one year, most preferably greater than one year, after one or more than one application of the formulation. Application of the active agent formulation to skin or nails can help repair damaged disulfide bonds due to natural wear and tear or natural aging.

Abstract: A method for colouring hair. The method comprises the formation of a first plurality of coated hair fibre portions by applying a first composition to a first plurality of hair fibre portions and subsequently styling the hair. The first plurality of coated hair fibre portions is contacted with a second plurality of coated hair fibre portions but does not comprise the application of a solid barrier means in order to separate the first plurality of coated hair fibre portions from the second plurality of coated hair fibre portions. The composition comprises from about 0.2% to about 20% of viscosity-increasing agent and the viscosity-increasing agent is selected from the group consisting of: clays; polysaccharides; silicas; block copolymers of polypropylene oxide (PPO) and polyethylene oxide (PEO); and mixtures thereof. Also provided are a hair colouring composition being in ready to use form, the use of the composition, a developing formulation, and a process for creating a hair colouring composition.

Abstract: Decorative polish compositions for nails are disclosed, as well as a kit including the same, and a method of decorating nails with the compositions.

Abstract: This invention relates to a cosmetic combination product comprising a first cosmetic composition comprising glucosamine or one of the salts thereof, a second cosmetic composition comprising hyaluronic acid, and possibly a third cosmetic composition comprising collagen, a cosmetic composition comprising glucosamine or one of the salts thereof, hyaluronic acid, and possibly collagen, the uses thereof, in particular for inducing the synthesis of hyaluronic acid and as such combat aging of the skin affecting the keratinocytes and/or the fibroblasts and the dermis, as well as a cosmetic method that implements these combination products and compositions.

Abstract: Compositions including at least one dendritic silicone acrylate copolymer and at least one silicone elastomer resin, as well as methods of making such compositions and methods of applying such compositions to keratinous material are provided.

Abstract: Compositions including at least one dendritic silicone acrylate copolymer, at least one silicone elastomer resin, and at least one surface-treated pigment, as well as methods of making such compositions and methods of applying such compositions to keratinous material are provided.

Abstract: Compositions including at least one dendritic silicone acrylate copolymer and at least one surface-treated pigment, as well as methods of making such compositions and methods of applying such compositions to keratinous material are provided.

Abstract: Compositions including at least one silicone resin comprising at least one T unit and at least one silicone elastomer resin, as well as methods of making such compositions and methods of applying such compositions to keratinous material are provided.

Abstract: The present invention relates to a topcoat composition for long-wear lip compositions comprising at least one silicone film-forming agent, as well as to systems, kits and methods of treating, making-up and enhancing the appearance of lips, including a long-wear lip composition comprising at least one silicone film-forming agent and a topcoat composition for application to the long-wear lip composition.

Abstract: The present invention relates to the use of citrus fruit pieces, obtained by controlled osmotic dehydration of said citrus fruit in a sugar syrup, for mechanically exfoliating dead cells from the epidermis of the skin of a person. Said citrus fruit pieces include the peel and/or epicarp of said citrus fruit and have a furocoumarin compound content of less than 50 ppm.

Abstract: The present invention relates to the field of pharmaceutical and nutraceutical formulations, and, more specifically, to effervescent formulations of ornithine aspartate as well as processes for their manufacture. Formulations of ornithine aspartate according to the present invention comprise a gas generating component as well as an acid component releasing carbon dioxide upon contact with water. The invention provides a simple process for the manufacture of such formulations that are chemically pure and stable and exhibit high levels of effervescence. The process comprises the following steps: —granulation of an ornithine aspartate-mix comprising ornithine aspartate and a gas generating component, thus yielding granules G, —mixing the components of a final mix comprising granules G and an acid component, thus yielding an effervescent formulation of ornithine aspartate.

Abstract: Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis.

Abstract: The present invention relates to stabilized liquid formulations of Levothyroxine or a pharmaceutically acceptable salt thereof, intended for parenteral administration. Further this invention also describes process of preparing such compositions.

Abstract: The present invention discloses a method for administering SN-38-loaded polymeric micelles into the central nervous system of a human subject via a convection-enhanced delivery system. The convection-enhanced delivery is achieved by using an osmotic pump or an infusion pump. Further, SN-38-loaded polymeric micelles are administered into a target region of the brain of the subject.

Abstract: The invention relates to spherical nucleic acids for the delivery of lipid nucleic acid particles. The lipid nucleic acid particles containing one or more therapeutic agents are coated with an oligonucleotide shell to enhance delivery.

Abstract: The purpose of the present invention is to provide a disintegrating tablet having excellent tablet hardness and disintegrability, which is suitable for pharmaceuticals and various kinds of foods such as supplemental foods, nutrition function foods and health foods has been desired as highly convenient forms which can safely be taken by patients who have difficulty in swallowing drugs, elderly people, children, etc., and which can easily be taken without water irrespective of places; and a disintegrative particulate composition comprised in the disintegrating tablet. The present invention relates to a disintegrative particulate composition comprising a disintegrator component and micro-fibrillated cellulose, and a disintegrating tablet for pharmaceuticals or foods, comprising the disintegrative particulate composition, which has excellent tablet hardness and disintegrability.

Abstract: The present invention relates to a granular composition comprising essentially Tenofovir, wherein the composition is devoid of an excipient. Tenofovir granules of the present invention are prepared in twin-screw processor such that the content of total impurities in the prepared granules is less than 2.0%.

Abstract: The present invention relates to the formulation of Adenoviral vectors in an aqueous mixture or freeze dried composition in the presence of amorphous sugar and low salt concentration, its formulation as well as a method for obtaining the dried composition.

Abstract: Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.

Abstract: The present invention relates to controlled release pharmaceutical formulations comprising an atypical antipsychotic agent such as Paliperidone or pharmaceutical acceptable salt thereof in the form of a multi-layer tablet that provides zero order drug release. It also relates to a process for the preparation thereof.

Abstract: The invention provides ingestible solid phase comprising an intimate mixture of a water-soluble or water-insoluble polysaccharide component (e.g. dietary fibres) and a fatty acid glyceride component having a melting point of higher than 37° C.; this solid phase optionally being provided in particulate form. The invention further provides methods for preparing the ingestible solid phase and uses thereof.

Abstract: Provided herein is a method for producing a dosage form that can be customized according to a patient's needs. In particular, the invention relates to dosage forms comprising an erodible polymer and an active pharmaceutical agent, wherein the erodible polymer is designed to have a specified geometric shape. As described herein, the active agent is released from the dosage form as a function of the geometric shape of the erodible polymer.

Abstract: When preparing a soft capsule shell by forming a film from a composition for a soft capsule shell comprising a base containing either gelatin or a mixture of starch and carrageenan as a main component and a plasticizer containing sorbitol, maltitol and glycerin as main components, it is possible to provide a soft capsule in which the soft capsule shell thereof does not easily soften and the surface of the soft capsule shell is resistant to adherence and which has excellent gloss and transparency even if the plasticizer contains glycerin.

Abstract: The invention relates to microparticles comprising a crosslinked gel and methods for making and using same.

Abstract: A composition comprising a nanoparticle, wherein the nanoparticle comprises a polymer/copolymer conjugated to a moiety is disclosed. A method of forming a nanostructure includes stirring poly(lactide-co-glycolide (PLGA) and 11-Ethyl-3-(dimethylaminopropyl) carbodiimide (EDC) in CH2Cl2 to create a PLGA mixture, n-boc-ethyelenediamine and N,N-Diisopropylethylamine (DIEA) are added to the PLGA mixture to create a reaction mixture. The reaction mixture is then precipitated in cold diethyl ether to form a purified polymer, which is then dried. The dried and purified polymer is then reconstituted in CH2Cl2:TFA solution and stirred under inert conditions. The product of the reconstituting step is evaporated to form a clear viscous residue that is dissolved in CH2Cl2 and then precipitated in cold ether to form a polymer. These functional polymers can encapsulate a variety of bioactives forming nanosystems improving the performance of bioactives.

Abstract: Aqueous solution, comprising, in dissolved state,—at least one stilbenoid—at least one saccharide, and method for increasing the solubility of a stilbenoid in water

Abstract: A kit for reducing scarring comprises a first composition including resveratrol and a second composition including a primary agent selected from the group consisting of caffeine, caffeine metabolites, and mixtures thereof. A method of reducing scarring comprises applying to a wound or incision a first composition including resveratrol and applying to the wound or incision a second composition including a substance selected from the group consisting of caffeine, caffeine metabolites, and mixtures thereof.

Abstract: A cannabinoid-based pharmaceutical composition for the prevention and treatment of pathogenic viruses (particularly those causing hepatic related conditions such as hepatitis B and C), and most particularly for hepatitis C virus (HCV) infection, having a cannabidiol structure or a pharmaceutically acceptable salt thereof. A method for the prevention and treatment of pathogenic viruses (particularly those causing viral hepatic related conditions such as hepatitis B and C), and most particularly for HCV is also disclosed.

Abstract: The present invention relates to a combination comprising pterostilbeneor pterostilbene phosphate or a pharmaceutically acceptable salt thereof, a glutathione depleting agent and a cancer chemotherapeutic agent. The invention also relates to the medical use of this combination, in particular for the treatment and/or prevention of cancer.

Abstract: Curcumin and a pharmaceutically acceptable salt thereof are used in the preparation of drugs for antitumor associated syndrome. Also disclosed is the use of curcumin to improve anemia while inhibiting tumors.

Abstract: Provided are combinations comprising terbinafine or a pharmaceutically acceptable salt thereof and a NO source. The combination may be a synergistic combination. Also provided are methods of treating and/or preventing a fungal infection in a subject comprising administering terbinafine or a pharmaceutically acceptable salt thereof to the subject; and administering a NO source to the subject, thereby treating and/or preventing the fungal infection in the subject. The dose of terbinafine or a pharmaceutically acceptable salt thereof and the dose of the NO source administered to the subject may achieve a synergistic effect.

Abstract: Disclosed herein are methods of treating one or more tumors by administering to the subject a therapeutically effective amount of a combination of RAD1901 or solvates (e.g., hydrate) or salts thereof and one or more second therapeutic agent(s) (e.g., everolimus). The cancer is an estrogen-dependent cancer, such as breast cancer, ovarian cancer, colon cancer, endometrial cancer, or prostate cancer.

Abstract: The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.

Abstract: The present invention relates to a method of treating or preventing cellular dysfunction and death caused by genetic, degenerative, toxic, traumatic, ischemic, infectious, neoplastic and inflammatory diseases and aging—and their neurological symptoms and manifestations, which includes administering d-methadone, beta-d-methadol, alpha-l-methadol, beta-l-methadol, alpha-d-methadol, acetylmethadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, beta-d-acetylmethadol, beta-l-acetylmethadol, d-alpha-normethadol, l-alpha normethadol, noracetylmethadol, dinoracetylmethadol, methadol, normethadol, dinormethadol, EDDP, EMDP, d-isomethadone, normethadone, N-methyl-methadone, N-methyl-d-methadone, N-methyl-l-methadone, l-moramide, levopropoxyphene, pharmaceutically acceptable salts, or mixtures thereof, including deuterated and tritium analogues, whether isolated from its enantiomer or synthesized de novo.

Abstract: The treatment of diabetes mellitus with excellent hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration. A composition for treating diabetes mellitus with hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration, and the composition has branched-chain amino acids and salts of biguanide derivatives and derivatives of biguanide derivatives or branched-chain amino acids as the active components. The composition will be more effective when leucine, isoleucine, or valine is included as branched-chain amino acids, and metformin as the biguanide derivative.

Abstract: The present invention relates to TRPV1 selective agonist compositions including a capsaicinoid, a surfactant and an extended release agent, and to methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.

Abstract: The present invention relates to TRPV1 selective agonist compositions including a capsaicinoid, a surfactant and an extended release agent, and to methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.

Abstract: The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.

Abstract: The invention relates novel pharmaceutical use of kaurane compounds of formula (I) in treating and preventing cardiac hypertrophy and myocardium remodeling. The said compounds also can significantly ameliorate pulmonary hypertension and preventing vascular hypertrophy. The said compounds can also be used to suppress fibrosis and to treat erection dysfunction, neurological degenerations and other related diseases by modulating cGMP or cAMP signal pathway and/or by reducing reactive oxygen species (ROS). Wherein R1: hydrogen, hydroxyl or alkoxy. R2: carboxyl, carboxylate, acyl halides, aldehyde, methyl-hydroxyl, and ester, acylamide, acyl or ether group hydrolysable to carboxyl. R3, R4, R5, R6, R8: independently, oxygen, hydroxyl, methyl-hydroxyl, and ester or alkoxymethyl group hydrolysable to methyl-hydroxyl. R7: methyl, hydroxyl, and ester or alkoxymethyl hydrolysable to methyl-hydroxyl. R9: methylene or oxygen.

Abstract: A method is described for treating a scar with an effective amount of adapalene or salts thereof, which is administrated to the patient in need thereof. Optionally, the administered adapalene is in a quantity of 0.3% by weight relative to the total weight of the composition.

Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof and an anti-cancer composition.

Abstract: A method for administering citrulline to a patient during surgery without filtration of the hemolysis to reduce the uncoupling of eNOS enzyme dimer that leads to cardiopulmonary bypass-induced pulmonary injury.

Abstract: The present invention discloses oral compositions for nourishment a mammalian subject which comprises steviol glycoside, citric acid monohydrate, monosodium glutamate and/or glycine. These compositions, being highly palatable, increase consumption of said composition, further configured to decrease mortality rate, increase weight gain, reduced use of either antibiotics or milk replacers and improve small intestine anatomy of said mammalian.

Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of neurological diseases and disorders involving administration of trans 10-HDA. In particular, the methods of the present invention are useful in the treatment and/or prophylaxis of acquired or progressive neurodevelopmental disorders and conditions in mammals. More particularly, methods are taught herein for the treatment and/or prophylaxis of diseases and disorders such as autism spectrum disorders.

Abstract: An application of omega-3 and/or omega-6 fatty acid(s) for the therapeutic treatment of the human or animal body in the case of an impaired sphingolipid metabolism, in particular in the case of impaired sphingolipid synthesis and/or excessive sphingolipid degradation. The agent is applied in the case of missing, reduced and/or defective formation of a sphingomyelin synthase enzyme in the body, in particular the enzyme sphingomyelin synthase 1 or the enzyme sphingomyelin synthase 2. The application has proved to be useful in the case of a defect of the sphingomyelin synthase 1 gene or of the sphingomyelin synthase 2 gene. The omega-3 and/or omega-6 fatty acid(s) preferably comprise(s) polyunsaturated omega-3 and/or omega-6 fatty acid(s), preferably EPA, DHA, DPA, ETA, 21:5n3 and/or SDA. A method for determining a cause of a disease in an animal or a human being and a device for carrying out the method are also provided.

Abstract: This invention relates to methods for improving the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6's (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.

Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.